Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature of the blood-brain barrier. The findings, in mouse models and isolated human brain tissue, were published in the February 17 online issue of Nature Materials. They demonstrate the potential of this technology to pave the way for future treatments for a wide range of conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis, brain cancer, and drug addiction.

In a paper published in National Science Review, an international team of scientists report a coordination nanomedicine (ZnDHT NM) featuring cascade specific Fe³⁺ capturing and in situ catalysis for achieving tumor catalysis-enhanced differentiation therapy. This nanomedicine can simultaneously treat cancer stem-like cells (CSCs) and bulk tumor cells by interfering with tumor Fe metabolism and redox homeostasis, thereby effectively inhibiting tumor growth, recurrence and metastasis.

This study utilizes bibliometric analysis to investigate the research landscape of FAP-directed cancer theranostics, focusing on the development and application of radiotracers based on quinoline-based FAP inhibitors (FAPIs).